OKYO Pharma (OKYO) Total Non-Current Liabilities (2023 - 2025)
OKYO Pharma (OKYO) reported Total Non-Current Liabilities of $8.0 million for Q3 2025, down 20.03% year-over-year from $10.0 million in Q3 2024, and down 12.79% quarter-over-quarter from $9.1 million in Q1 2025.
OKYO Pharma (OKYO) Total Non-Current Liabilities (2023 - 2025) Analysis & Trends
OKYO Pharma (OKYO) has 3 years of Total Non-Current Liabilities data on file, last reported at $8.0 million in Q3 2025.
- Total Non-Current Liabilities for Q3 2025 came in at $8.0 million, down 20.03% year-over-year; the trailing twelve-month figure through Sep 2025 was $8.0 million (down 20.03% YoY), and the FY2025 annual result was $9.1 million, up 24.65% from the prior year.
- Total Non-Current Liabilities eased to $8.0 million in Q3 2025 per OKYO's latest filing, from $9.1 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $10.0 million in Q3 2024 and troughed at $7.3 million in Q1 2024.
- A 3-year average of $8.5 million and a median of $8.2 million in 2023 frame the typical range for Total Non-Current Liabilities.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 24.65% in 2025 and fell as far as 20.03% in 2025.
- A 3-year view of Total Non-Current Liabilities shows it stood at $8.2 million in 2023, then rose by 21.09% to $10.0 million in 2024, then slipped by 20.03% to $8.0 million in 2025.
- Business Quant data shows OKYO's Total Non-Current Liabilities at $8.0 million in Q3 2025, $9.1 million in Q1 2025, and $10.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 42,980.09 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 64.76 Mn |
| 10 | OKYO Pharma | 244.98 Mn | 240.76 Mn | - | 7.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 7.97 Mn |
| Mar 31, 2025 | 9.13 Mn |
| Sep 30, 2024 | 9.96 Mn |
| Mar 31, 2024 | 7.33 Mn |
| Sep 30, 2023 | 8.23 Mn |